The great #ISSVA debates meeting 2025 meeting has come to an end. Nothing compares to F2F discussions and networking. Looking forward to the ISSVA World Congress 2026 in #Philadelphia #vascapa #hevas #CMTC #VASCERN #LE&RN #ESL #ISL #vascular #lymphatic #syndrome #hemangioma #theranostic #repurposing
April 26, 2025 at 11:00 AM
The great #ISSVA debates meeting 2025 meeting has come to an end. Nothing compares to F2F discussions and networking. Looking forward to the ISSVA World Congress 2026 in #Philadelphia #vascapa #hevas #CMTC #VASCERN #LE&RN #ESL #ISL #vascular #lymphatic #syndrome #hemangioma #theranostic #repurposing
If you are interested in the clinical aspects of lymphatic diseases, don't miss the 30th ISL World Congress of Lymphology. #lymph @vascern.bsky.social
#issva #theralymph
#issva #theralymph
May 9, 2025 at 12:00 PM
If you are interested in the clinical aspects of lymphatic diseases, don't miss the 30th ISL World Congress of Lymphology. #lymph @vascern.bsky.social
#issva #theralymph
#issva #theralymph
International Conference on Vascular Anomalies: Translating basic research into new therapies (VAC 2025)! : Exciting program, including novel preclinical models, drugs, and most recent results from clinical trials! lnkd.in/e6_BbzQF. Registrations: lnkd.in/dzTfFVej
#VASCAPA #HEVAS #CMTC #EVBO #ISSVA
#VASCAPA #HEVAS #CMTC #EVBO #ISSVA
January 23, 2025 at 4:07 PM
International Conference on Vascular Anomalies: Translating basic research into new therapies (VAC 2025)! : Exciting program, including novel preclinical models, drugs, and most recent results from clinical trials! lnkd.in/e6_BbzQF. Registrations: lnkd.in/dzTfFVej
#VASCAPA #HEVAS #CMTC #EVBO #ISSVA
#VASCAPA #HEVAS #CMTC #EVBO #ISSVA
Today VASCA@Berlin… next: ISSVA@Paris www.issva.org/2025
ISSVA Debates & Updates 2025 | ISSVA DEBATES & UPDATES 2025
www.issva.org
February 10, 2025 at 9:47 PM
Today VASCA@Berlin… next: ISSVA@Paris www.issva.org/2025
International Conference on Vascular Anomalies: Translating basic research into new therapies (VAC 2025)! : lnkd.in/e6_BbzQF. Don't miss the event. The congress networking dinner nearly sold out! A few seats left for congress participation. lnkd.in/dzTfFVej
#VASCAPA #HEVAS #CMTC #EVBO #ISSVA
#VASCAPA #HEVAS #CMTC #EVBO #ISSVA
February 6, 2025 at 5:23 PM
International Conference on Vascular Anomalies: Translating basic research into new therapies (VAC 2025)! : lnkd.in/e6_BbzQF. Don't miss the event. The congress networking dinner nearly sold out! A few seats left for congress participation. lnkd.in/dzTfFVej
#VASCAPA #HEVAS #CMTC #EVBO #ISSVA
#VASCAPA #HEVAS #CMTC #EVBO #ISSVA
Three other interesting meetings in 2025 in Europe on vascular anomalies and lymphedema: #ISSVA debates and Updates,Paris (www.issva.org/2025); 1st European #Lymphatic Symposium,Toulouse (european-lymphatic-symposium.com), & the ISL World Congress of Lymphology,Antalya (www.isl2025lymphology.org).
February 20, 2025 at 11:13 AM
Three other interesting meetings in 2025 in Europe on vascular anomalies and lymphedema: #ISSVA debates and Updates,Paris (www.issva.org/2025); 1st European #Lymphatic Symposium,Toulouse (european-lymphatic-symposium.com), & the ISL World Congress of Lymphology,Antalya (www.isl2025lymphology.org).
Congratulations Emmanuel on showing how #sirolimus treatment can be adapted. #patients with #slow-#flow #vascular #malformations have #symptom reduction even with #intermittent dosing. A big step forward in the #multimodal management of VAs. #VASCERN #VASCAPA #CMTC #HEVAS #ISSVA #EVDays #Lymph
December 17, 2025 at 7:25 AM
Congratulations Emmanuel on showing how #sirolimus treatment can be adapted. #patients with #slow-#flow #vascular #malformations have #symptom reduction even with #intermittent dosing. A big step forward in the #multimodal management of VAs. #VASCERN #VASCAPA #CMTC #HEVAS #ISSVA #EVDays #Lymph
Three other interesting meetings in 2025 in Europe on vascular anomalies and lymphedema: #ISSVA debates and Updates,Paris (www.issva.org/2025); 1st European #Lymphatic Symposium,Toulouse (european-lymphatic-symposium.com), and the ISL World Congress of Lymphology, Antalya(www.isl2025lymphology.org).
February 20, 2025 at 11:15 AM
Three other interesting meetings in 2025 in Europe on vascular anomalies and lymphedema: #ISSVA debates and Updates,Paris (www.issva.org/2025); 1st European #Lymphatic Symposium,Toulouse (european-lymphatic-symposium.com), and the ISL World Congress of Lymphology, Antalya(www.isl2025lymphology.org).
I hope these pathways will help both junior and senior physicians to manage these patients , and to those affected by these vascular diseases to obtain faster a definite diagnosis. #vascapa #vascern #cmtc #hevas #vascern #capillary #malformation #evbo #navbo #issva #leducq #theralymph
March 5, 2025 at 7:13 AM
I hope these pathways will help both junior and senior physicians to manage these patients , and to those affected by these vascular diseases to obtain faster a definite diagnosis. #vascapa #vascern #cmtc #hevas #vascern #capillary #malformation #evbo #navbo #issva #leducq #theralymph
Exciting 1st day at #iDR26 on #drug #repurposing. Academics, companies, funders, policymakers & patients, gathered to discuss how to #repurpose #medicines for #diseases with unmet medical needs, incl. #vascular anomalies. #VASCERN #VASCAPA #HEVAS #CMTC #Eurordis #WELRI #deDuveInstitute #FNRS #ISSVA
May 12, 2026 at 2:48 PM
Exciting 1st day at #iDR26 on #drug #repurposing. Academics, companies, funders, policymakers & patients, gathered to discuss how to #repurpose #medicines for #diseases with unmet medical needs, incl. #vascular anomalies. #VASCERN #VASCAPA #HEVAS #CMTC #Eurordis #WELRI #deDuveInstitute #FNRS #ISSVA
The virtual #European #Angiology Days (EADays) 2025 are just over. Great presentations and discussions. And easy access - no travel !! Stay tuned for the #EADays – VAS-INT 2026 meeting, which will take place virtually from 27 to 29 November, 2026. #VASCERN #VASCAPA #HEVAS #CMTC #ISSVA #NAVBO #EVBO
December 15, 2025 at 1:41 PM
4 days left before we the International Conference on Vascular Anomalies: Translating basic research into new therapies (VAC 2025)! Exciting program on novel preclinical models, drugs and results from clinical trials! lnkd.in/e6_BbzQF. Register at: lnkd.in/dzTfFVej #VASCAPA #HEVAS #CMTC #EVBO #ISSVA
February 6, 2025 at 5:20 PM
4 days left before we the International Conference on Vascular Anomalies: Translating basic research into new therapies (VAC 2025)! Exciting program on novel preclinical models, drugs and results from clinical trials! lnkd.in/e6_BbzQF. Register at: lnkd.in/dzTfFVej #VASCAPA #HEVAS #CMTC #EVBO #ISSVA
The latest edition of Clinics in Plastic Surgery just released. Link to download the VENOUS MALFORMATION chapter by Dr Julien Coulie from our Vascular Anomaly Centre for free until 25/8/2026. Enjoy reading it. #VASCAPA #CMTC #HEVAS #VASCERN #ISSVA
authors.elsevier.com/a/1nOYuLPnEr...
authors.elsevier.com/a/1nOYuLPnEr...
July 8, 2026 at 9:08 AM
Exciting #ISSVA 2026. 100 presentations, posters, intense discussions and sponsored sessions. A great keynote by Taija Makinen. A touching tribute to the late founder, John Mulliken, underscoring curiosity, accuracy and collaboration. ISSVA Dublin 5-7 May 2027.
#VASCERN -VASCA #VASCAPA #HEVAS #CMTC
#VASCERN -VASCA #VASCAPA #HEVAS #CMTC
May 22, 2026 at 2:46 PM
#ISSVA 2026 has started. Great to meet again friends and colleagues to discuss #vascular #anomalies. #vascapa #hevas #cmtc #deduveinstitute #Vascern
May 19, 2026 at 11:50 PM
#ISSVA 2026 has started. Great to meet again friends and colleagues to discuss #vascular #anomalies. #vascapa #hevas #cmtc #deduveinstitute #Vascern
Fabian’s great work: Volumetric perfusion fraction change in MR angiography for monitoring sclerotherapy-related changes in peripheral #venous #malformations published. Free access until 13/6/2026: authors.elsevier.com/c/1m~tx,GNpk...
#VASCERN #VASCAPA #HEVAS #CMTC #Welbio #deDuveInstitute #ISSVA
#VASCERN #VASCAPA #HEVAS #CMTC #Welbio #deDuveInstitute #ISSVA
April 28, 2026 at 1:53 PM
Fabian’s great work: Volumetric perfusion fraction change in MR angiography for monitoring sclerotherapy-related changes in peripheral #venous #malformations published. Free access until 13/6/2026: authors.elsevier.com/c/1m~tx,GNpk...
#VASCERN #VASCAPA #HEVAS #CMTC #Welbio #deDuveInstitute #ISSVA
#VASCERN #VASCAPA #HEVAS #CMTC #Welbio #deDuveInstitute #ISSVA
🟢 #$PVLA — Clinical Readout
New SELVA Phase 3 Data Presented at ISSVA 2026 - QTORIN Rapamycin for Microcystic Lymphatic Malformations
Additional data from the Phase 3 SELVA study of QTORIN rapamycin presented at the ISSVA World Congress 2026. In participants ag…
https://biostock.app/symbols/PVLA
New SELVA Phase 3 Data Presented at ISSVA 2026 - QTORIN Rapamycin for Microcystic Lymphatic Malformations
Additional data from the Phase 3 SELVA study of QTORIN rapamycin presented at the ISSVA World Congress 2026. In participants ag…
https://biostock.app/symbols/PVLA
May 20, 2026 at 8:42 PM
🟢 #$PVLA — Clinical Readout
New SELVA Phase 3 Data Presented at ISSVA 2026 - QTORIN Rapamycin for Microcystic Lymphatic Malformations
Additional data from the Phase 3 SELVA study of QTORIN rapamycin presented at the ISSVA World Congress 2026. In participants ag…
https://biostock.app/symbols/PVLA
New SELVA Phase 3 Data Presented at ISSVA 2026 - QTORIN Rapamycin for Microcystic Lymphatic Malformations
Additional data from the Phase 3 SELVA study of QTORIN rapamycin presented at the ISSVA World Congress 2026. In participants ag…
https://biostock.app/symbols/PVLA
🟢 #$RLAY — Clinical Readout
Phase 2 ReInspire Trial Initial Data - Zovegalisib in PIK3CA-Driven Vascular Anomalies (60% VRR at ISSVA 2026)
Initial data from Phase 2 ReInspire trial of zovegalisib in PIK3CA-driven vascular anomalies presented at ISSVA World Cong…
https://biostock.app/symbols/RLAY
Phase 2 ReInspire Trial Initial Data - Zovegalisib in PIK3CA-Driven Vascular Anomalies (60% VRR at ISSVA 2026)
Initial data from Phase 2 ReInspire trial of zovegalisib in PIK3CA-driven vascular anomalies presented at ISSVA World Cong…
https://biostock.app/symbols/RLAY
May 19, 2026 at 12:52 PM
🟢 #$RLAY — Clinical Readout
Phase 2 ReInspire Trial Initial Data - Zovegalisib in PIK3CA-Driven Vascular Anomalies (60% VRR at ISSVA 2026)
Initial data from Phase 2 ReInspire trial of zovegalisib in PIK3CA-driven vascular anomalies presented at ISSVA World Cong…
https://biostock.app/symbols/RLAY
Phase 2 ReInspire Trial Initial Data - Zovegalisib in PIK3CA-Driven Vascular Anomalies (60% VRR at ISSVA 2026)
Initial data from Phase 2 ReInspire trial of zovegalisib in PIK3CA-driven vascular anomalies presented at ISSVA World Cong…
https://biostock.app/symbols/RLAY